Depression and anxiety during pregnancy and the postpartum period in women with epilepsy: A review of frequency, risks and recommendations for treatment  by H. Bjørk, Marte et al.
Seizure 28 (2015) 39–45Review
Depression and anxiety during pregnancy and the postpartum
period in women with epilepsy: A review of frequency,
risks and recommendations for treatment
Marte H. Bjørk a,b,*, Gyri Veiby a,b, Bernt A. Engelsen a,b, Nils Erik Gilhus a,b
aDepartment of Clinical Medicine, University of Bergen, Bergen, Norway
bDepartment of Neurology, Haukeland University Hospital, Bergen, Norway
A R T I C L E I N F O
Article history:
Received 3 November 2014
Received in revised form 6 February 2015
Accepted 10 February 2015
Keywords:
Perinatal
Seizure
Psychiatry
Antiepileptic drugs
Antidepressants
Postnatal
A B S T R A C T
Purpose: To review available data and provide treatment recommendations concerning peripartum
depression, anxiety and fear of birth in women with epilepsy (WWE).
Method: The PubMed, the LactMed, the DART and the Cochrane database were searched for original
articles concerning psychiatric disease in the peripartum period in WWE.
Results: Point prevalence of depression from 2nd trimester to 6 months postpartum ranged from 16 to
35% in women with epilepsy compared to 9–12% in controls. The highest estimates were found early in
pregnancy and in the perinatal period. Anxiety symptoms 6 months postpartum were reported by 10 and
5%, respectively. Fear of birth symptoms were increased in primiparous WWE compared to controls.
Previous psychiatric disease, sexual/physical abuse, antiepileptic drug (AED) polytherapy, and high
seizure frequency emerged as strong risk factors. Depressed WWE rarely used antidepressive medication
during pregnancy. No evidence was available concerning treatment effects or impact on the developing
child.
Conclusion: Peripartum depression is frequent in WWE and seldom medically treated. Health personnel
should screen WWE for psychiatric disease and risk factors during pre-pregnancy planning, pregnancy
and postpartum follow up. Treatment decisions should rely on efﬁcacy and safety data in peripartum
patients without epilepsy and non-pregnant people with epilepsy. Consequences of in utero exposure to
AED therapy in combination with antidepressants are not known, and non-pharmacological treatment
should be tried ﬁrst.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
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Peripartum depression and anxiety are the most common
complications of childbearing, and associated with substantial
adverse effects on pregnancy outcome and the developing child
[1,2]. The disorders encompass major and minor depressive
episodes and anxiety disorders that occur during pregnancy orAbbreviations: AED, antiepileptic drugs; CBT, cognitive behavioral therapy; CYP,
cytochrome P450; MBRN, Medical Birth Registry of Norway; SSRI, selective
serotonin reuptake inhibitor; SNRI, serotonin noradrenaline reuptake inhibitor;
WWE, women with epilepsy.
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E-mail addresses: mebk@helse-bergen.no, marte.bjork@gmail.com,
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1059-1311/ 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.within the ﬁrst 12 months after delivery [3]. The diagnostic criteria
are otherwise similar to anxiety disorders and depressive episodes
outside the peripartum period [2,4].
Frequency estimates of maternal psychiatric disease vary with
the diagnostic criteria and tools used, the time period under
consideration and the study population [5]. A systematic review of
28 studies from developed countries assessing peripartum
depression by clinical assessment or structured interview found
a point prevalence of 6.5–12.5% at different time points during
pregnancy and the ﬁrst postpartum year [3]. A similar diagnostic
approach revealed anxiety disorders in 4% of women at a 6 weeks
routine postnatal visit [6].
Consequences of depression and anxiety are often more severe
in the peripartum period than during other life periods. Suicide in
the frame of psychiatric disease is the leading cause of maternal
death in the United Kingdom [7]. The majority of suicides were
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circumstances [8]. Mother–infant interactions in the presence
of depression may be characterized by less face-to-face play
behavior, positive touching and appropriate vocal behavior, and
more maternal hostility, unresponsiveness and self-focus
[5,9,10]. Thoughts of harming the infant is frequent in depressed
mothers [11], and the risk of physical child abuse is increased
[12]. There is an association between maternal pregnancy-related
depression and child behavioral problems [9,13,14], impaired
language [15,16], cognitive development [14] and physical health
problems [13,17].
People with epilepsy are especially vulnerable to depression
and anxiety [18]. The frequency of mood disorders ranges from 10 to
50%, and anxiety disorders from 11 to 46% in adult epilepsy cohorts,
depending on the prevalence estimate and whether study popula-
tions have been gathered from epilepsy centers or the general
population [18,19]. These disorders are among the strongest
predictors of quality of life in people with epilepsy and related to
poor seizure control, AED side effects, cognitive complaints, suicidal
ideation and high economical costs for the society [20–22].
Psychiatric implications of epilepsy in pregnancy have received
little attention. The challenges related to preventing epileptic
seizures and teratogenic effects of antiepileptic medication
probably overshadow concerns about psychiatric symptoms.
However, psychological health is of vital importance for the
mother in order to maintain care for herself and her children.
Health personnel should therefore be aware of the frequency,
warning signs, consequences and treatment options of psychiatric
disorders during pregnancy in patients with epilepsy.
2. Methods
We searched the Cohrane library, the TOXNET (DART), the
LactMed, and the PubMed databases using combinations of the
keywords: ‘‘epilepsy’’, ‘‘postpartum’’, ‘‘depression’’, ‘‘fear of birth’’,
‘‘anxiety’’, ‘‘pregnancy’’, ‘‘SSRI’’, ‘‘SNRI’’ and ‘‘peripartum’’. Based on
title or abstract, we selected all English language original articles
concerning psychiatric disease in patients with epilepsy during
pregnancy or in the postpartum period. A selection of papers
concerning peripartum psychiatric disease in general as well as
psychiatric disease in epilepsy was also included.
3. Results: peripartum psychiatric disorders in epilepsy
3.1. Background factors
Pregnant women with epilepsy (WWE) are sociodemographi-
cally and psychosocially different from other pregnant women.
This should be accounted for when interpreting data and making
treatment decisions. In two Norwegian population-based studies
of social aspects in pregnant WWE, women taking AEDs had a high
frequency of low education, low income, and unemployment due
to disability. Four percent were single mothers [23]. More than 20%
reported previous sexual and/or physical abuse, and 1 in 4 stated
that the pregnancy was unplanned [24].
3.2. Frequency
Five studies have investigated peripartum depression in WWE
(Table 1). General anxiety was included in one study and fear of
birth was investigated in another study. There were no studies
examining treatment effects or consequences for child outcome.
Turner et al. found the point prevalence of depression 5–8
weeks postpartum to be more than 3 times higher than in healthy
control women in two studies [25,26]. After an initial evaluation
with the Edinburgh Postpartum Depression Score (EPDS), the ﬁnaldiagnosis of postpartum depression was done after an unblinded
clinical psychiatric interview that raised the percentage of affected
women with 6% in the epilepsy group, but did not change the
prevalence in the control group. Possibly, EDPS is less sensitive for
depression in WWE than in other women. Alternatively awareness
of the epilepsy group affected the prevalence ratings. Strengths of
these studies included a validated epilepsy diagnosis, prospective
follow up, and detailed clinical information.
In a prospective uncontrolled patient cohort from a tertiary
epilepsy center, Galanti et al. found depression in 25% of epilepsy
patients 12 weeks postpartum [27]. In a population-based
Norwegian cohort including more than 100,000 pregnancies,
0.7% from WWE, Reiter et al. found that self-reported symptoms of
depression and/or anxiety were almost doubled in the epilepsy
cohort that used AEDs (Table 1) [23]. However, the frequencies of a
diagnosis of depression and anxiety were similar among women
with and without epilepsy, possibly pointing to underacknowlege-
ment of psychiatric symptoms in WWE. In a study by Bjørk et al.,
the same cohort was followed throughout pregnancy until 3 years
after delivery using a diagnostic screening tool for depression and
anxiety [24]. Peripartum period-prevalence of depression was
higher in women with AED treated epilepsy than in women
without epilepsy (32 vs. 19%) and in women with other chronic
disease (23%). Point prevalence was higher at all time points.
Signiﬁcantly fewer of depressed WWE used antidepressive
medication during the pregnancy compared to women without
epilepsy and to women with other chronic diseases (4.6 vs.
13.2 and 15.5% respectively). An attempt to reduce total drug load
in pregnancy might explain why AED treated WWE seldom used
antidepressants. However, those who did not use AED during
pregnancy had an even lower frequency of antidepressants (2.6%).
Hence, less use of medication against depression could not be
explained by concomitant AED medication [24]. Bjork et al. also
found that the point prevalence of general anxiety symptoms
6 months after delivery was 10% in WWE, 5% in women without
epilepsy, and 7% in women with other chronic disease
[24]. Strengths of these two studies include a less selected
epilepsy cohort and a long follow-up period. Methodological
weaknesses are self-reported diagnosis of epilepsy and lack of a
clinical psychiatric evaluation.
3.3. Fear of childbirth
Severe fear of childbirth is experienced by 5–6% of women in
general during pregnancy and includes fear of pain, incapacity to
give birth, losing control, parenting capacity, concerns about
the health of the baby, as well as delivery complications [29–
32]. The condition is related to previous psychiatric disease, sexual
abuse, requests for caesarian section, previous complicated
deliveries, and low partner support [30,31,33]. Psychotherapeutic
interventions have proved effective and represent ﬁrst line therapy
[30,33].
No difference in fear of birth frequency diagnosed with the
Wilma Delivery Expectancy Questionnaire was found in 50 previ-
ous psychiatric healthy WWE and 50 matched controls (54 vs 52%
respectively) [28]. However, nulliparous WWE reported a signiﬁ-
cantly higher mean score than controls. Strengths of the study
included a validated diagnosis of epilepsy and available clinical
epilepsy information. However, as only psychiatric and somatic
healthy women were included, the generalizability to epilepsy
populations is uncertain.
3.4. Risk factors
Galanti et al. reported that AED polytherapy, multiparity and
tonic clonic seizures during the postpartum period were related to
Table 1
Point prevalence of postpartum depression (PPD) during and after pregnancy in women with AED treated epilepsy.
Author Population Epilepsy type Number Diagnostic tool Time of assessment Results
Turner
et al. [25]
Epilepsy clinic Generalized 51% Epilepsy: 35 EDPS >9 5–8 weeks
postpartum
PPD epilepsy: 35%
Focal 49%
(77% symptomatic)
Controls: 35 Clinical
interview
Controls: 11%
Psychiatric healthy,
educated women
EDPS:
Epilepsy 29%
Controls 11%
Turner
et al. [28]
Epilepsy clinic Generalized 45% Epilepsy: 35 EDPS >9 5–8 weeks
postpartum
PPD epilepsy: 39%
Focal 55%
(33% symptomatic)
Controls: 35 Clinical
interview
Controls: 12%
Psychiatric healthy,
educated women.
Galanti
et al. [27]
Tertiary
epilepsy center
30% generalized
(18% juvenile
myoclonic epilepsy)
56 Epilepsy BDI  12 Within 12 weeks
postpartum
PPD 25%
63% focal
Reiter
et al. [23]
Population
based cohort
52.5% focal, 25%
primary generalized
(15% juvenile myoclonic
epilepsy)*
Epilepsy 329
pregnancies
SCL-5
mean > 1.75
Gestational
week 13–17
2nd trimester
depression/anxiety
Reference: 106,224
pregnancies
Epilepsy 19%
Reference
cohort: 11%
Bjørk
et al. [24]
Population
based cohort
52.5% focal, 25% primary
generalized (15% juvenile
myoclonic epilepsy)*
Epilepsy 319
pregnancies
SCL-8 mean > 1.75 Gestational
week 30
3rd trimester
depression
Reference: 98,282
pregnancies
6 months
postpartum
Epilepsy: 17%
Reference: 9%
PPD:
Epilepsy: 16%
Reference: 10%
EDPS: Depression diagnosed by the Edinburgh postnatal depression scale.
BDI: Depression diagnosed by the Beck depression inventory.
SCL-5: Hopkins symptom checklist 5 item (3 questions concerning depression, 2 concerning anxiety.
SCL-8: Hopkins symptom checklist 8 item (4 questions concerning depression).
* Based on hospital records from a subcohort (n = 40).
M. H. Bjørk et al. / Seizure 28 (2015) 39–45 41depression [27]. Lamotrigine was not associated with reduced risk
compared to other AEDs. On the contrary, depression rates were
numerically higher in lamotrigine treated groups, independent of
former episodes of major depression. The authors concluded that
mood-stabilizing AEDs did not reduce the risk of postnatal
depression [27]. In contrast, Turner et al., did not ﬁnd signiﬁcant
associations between postpartum depression and any risk factors,
possibly due to low power [25,26].
We found that the risk of peripartum depression and/or
anxiety was highest in patients that used AEDs, especially in
polytherapy users [24]. Patients with high AED doses and/or
plasma concentrations had higher risk than those with lower
doses and/or plasma concentrations. No risk-reducing effect was
found for any speciﬁc AED. A subgroup with high seizure
frequency during pregnancy had the highest risk of peripartum
depression and/or anxiety (Fig. 1). Long-term outcome was less
favorable for WWE with a history of anxiety and/or depression or
previous sexual/physical abuse, but prognosis was otherwise
similar between groups. For WWE it was less common that
depressive symptoms in the peripartum period represented the
ﬁrst depressive episode. The association between peripartum
depression and/or anxiety and psychosocial risk factors was
similar in WWE, women without epilepsy, and women with other
chronic diseases [24].
Fear of birth was related to high seizure frequency. WWE were
more often afraid of congenital malformations, while the control
women more frequently feared pain during labor [28].4. Discussion and recommendations
4.1. Risk mechanisms
Peripartum depression in WWE is most frequent early in
pregnancy and 0–12 weeks postpartum. This is in line with studies
of women without epilepsy [3,4]. In women without epilepsy,
there may be a subset of postpartum depressions that are
speciﬁcally linked to childbirth, perhaps hormonally mediated.
However, the majority probably reﬂects a general psychological or
biological vulnerability to depression where childbirth represents
a triggering stressor [5]. In WWE, pregnancy related psychiatric
distress is highly associated with the disease and its treatment.
Treatment-resistant epilepsy particularly carries a high risk for
postpartum depression [24,27,28]. As previous psychiatric disease
is strongly related to depression and anxiety in pregnancy [34,35],
and WWE more often have a history of such disorders [23], these
women are already vulnerable. Outside of pregnancy, interictal
depression in epilepsy has a multifactorial etiology including
underlying neurobiological pathophysiology, psychosocial factors,
AED side effects, and health risk behaviors [20,22]. These
mechanisms probably operate also in pregnancy.
4.2. Child care
When caring for an infant, the unpredictability of seizures,
accompanying sense of vulnerability and fear of causing harm to
Fig. 1. Risk of peripartum depression and/or anxiety shown as unadjusted odds ratios with conﬁdence intervals in epilepsy subgroups with various risk factors.
Source: Printed with the kind permission of Epilepsia and Wiley. Copyright John Wiley and Sons 2014.
Table 2
Safe child care advise.
Child care safety issues
Maximize opportunity for bonding, but minimize risk
Avoid exhaustion. Share care at night
Breastfeed/bottle feed on ﬂoor
Use safe baby/childrens chair
Change on ﬂoor
Never bath child alone
Carrry child in secure carrycot up and down stairs
Contain child by safety gates, playpen, harness etc.
Make kitchen completely safe
Use dead man’s handle on prams
Teach older children what to do during seizures
Source: Adapted from Fox et al. [38].
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dropping the child due to myoclonic jerks or tonic clonic seizures,
or leaving the child unsupervised during a generalized seizure and
in the postictal period. In a survey of child care issues in mothers
with epilepsy, going outdoors and bathing the child were rated as
especially problematic [36]. Such fears are not unfounded. In a
group of 28 mothers with severe epilepsy that had not received
child-care advice before delivery, unfortunate events caused by
maternal seizures happened to 32% of their children during the
ﬁrst year [37]. This included two near-drowning accidents and
6 child droppings (one fatal). Inappropriate handlings of the child
during non-convulsive seizures, were also seen. The majority of the
incidents were preventable. In a control group of mothers with
epilepsy that had received advice on safe child care, unfortunate
events were very rare [37]. In order to prevent unnecessary
anxiety, child-expecting parents with epilepsy should be advised
on safe child care (Table 3) [38] and reassured that if such
measures are undertaken, harm to the child due to parent seizures
is unlikely. Also, such information should be conveyed to patients
with controlled epilepsy. Especially in the puerperium, parents
with a former controlled epilepsy can experience recurrence of
seizures and myoclonic jerks [37,38]. Since following advice often
requires the presence of another person, single mothers can be
especially vulnerable for anxiety related to the child care situation.Single motherhood is common in epilepsy populations [23], and
such women need extra support (Table 2).
4.3. AED treatment
AED therapy was associated with peripartum depression in
WWE in three studies, and AEDs assumed to be ‘‘mood stabilizing’’
did not reduce the risk [23,24,27]. Co-morbidity associated with
prescription of AEDs with psychotropic properties represents
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former psychiatric history. Also, it is difﬁcult to fully account for
the relationship between AED therapy and severity of epilepsy, as
exempliﬁed by the strong association between seizure frequency
and peripartum psychiatric symptoms.
In terms of side effects, the same AED may exhibit both positive
and negative psychotropic effects [39]. Carbamazepine, valproate,
oxcarbazepine, lamotrigine and pregabalin are believed to have
positive psychotropic effects, while phenobarbital, phenytoin,
vigabatrin, levetiracetam, topiramate, tiagabine, zonisamide and
felbamate are suspected to affect mood in a negative way
[20,39]. Anxiety can emerge after discontinuation of an AED with
anxiolytic properties [39]. However, observed positive effects on
mood in relation to anticonvulsant treatment do not necessarily
mean that such AEDs also have a therapeutic effect on depression
or anxiety disorders in people without epilepsy. Hard evidence for
a positive effect of AEDs on psychiatric disease only exists from
trials on patients with psychiatric disease without epilepsy [40]. In
epilepsy, underlying etiology and the spectrum and symptoms of
mood disorders can be different compared to other populations
[22]. Patients often have complicating factors such as AED
polytherapy and cognitive dysfunction. Add-on therapy with AEDs
with positive psychotropic effects were claimed to have some
effect on psychiatric symptoms in a recent review, but not more
useful than antidepressive medication or psychotherapy [41]. Due
to the negative associations between polytherapy and depression,
we do not recommend to treat depression or anxiety in relation to
pregnancy by add-on therapy with AEDs.
4.4. Antidepressive medication
A recent Cochrane review regarding treatment for moderate
postnatal depression in women without epilepsy favored selective
serotonin re-uptake inhibitors (SSRIs) over placebo in terms of
response and remission rates [2]. Maternal side effects were
frequently reported. There was insufﬁcient evidence to conclude
whether antidepressant or psychosocial treatments were more
effective. There were little data on potential effects on the mother–
child relationship [2].
Even though there are few methodologically adequate studies
on the efﬁcacy of antidepressants in epilepsy, it is assumed that
depressive symptoms in patients with epilepsy outside of
pregnancy respond well to treatment with SSRIs and selected
serotonin-norepinephrine reuptake inhibitors (SNRIs) [20]. Wors-
ening of seizures with initiation of a SSRI is rarely seen
[20,39,40]. In patients with concomitant AED use, citalopram,
escitalopram and venlafaxine are theoretically favorable to drugs
that inhibit cytochrome P450 (CYP) enzymes [40]. Conversely,
serum levels of most SSRIs and SNRIs can be reduced by CYP
inducers such as carbamazepine and phenytoin, and increased by
CYP inhibitors such as valproate [21,39,40]. Escitalopram, sertra-
line and venlafaxine are documented as effective for certain
anxiety disorders in patients without epilepsy, while other
conditions respond better to cognitive behavioral therapy (CBT),
or CBT in combination with antidepressants [21].
4.5. Antidepressants in pregnancy
Risks of adverse events related to antidepressants in pregnancy
have been widely studied. Both SSRIs and tricyclic antidepres-
sants pass via the placenta in considerable amounts. SSRIs are
assumed to be least harmful, and have in later years been
extensively prescribed in pregnancy [42]. There is concern that in
utero exposure may cause offspring adverse effects, especially
cardiac defects, respiratory distress, and low birth weight.
However, studies report conﬂicting results, probably due to themany confounders related to psychiatric disease [43]. Several
register-based clinical studies and preclinical data show a low
but signiﬁcant risk of persistent pulmonary hypertension, and an
increased risk of transient sleep-pattern disruption and transient
neonatal jitteriness and irritability [43,44]. Regarding long-term
offspring effects, some studies have found increased risk of
cognitive, behavioral and developmental problems, even after
adjusting for maternal mood disorders. A recent review concluded
that non-pharmacological treatment is recommended as ﬁrst line
therapy in pregnancy. However, it is not always a viable option.
Due to potentially serious consequences of maternal depression,
the need to initiate effective, rapid-onset therapies must be
weighed against the possible teratogenic potential of SSRIs
[43]. In WWE, an individual cost-beneﬁt evaluation is especially
important, as there are no data regarding consequences of
combining AEDs with SSRIs in pregnancy.
4.6. Antidepressants and breastfeeding
Antidepressants are lipid soluble and excreted in breast milk
[2], but the degree of exposure for the child is considerably lower
than in utero. Some case reports have described adverse events
such as sedation, poor feeding and disturbed sleep. There is no
evidence of long term adverse effects of antidepressants via breast
milk, but studies are lacking. Drug concentrations can accumulate
in premature or sick babies with compromised kidney and liver
function [45], and also with the tricyclic antidepressant doxepin.
Signiﬁcant drug infant levels are more likely with the SSRIs
ﬂuoxetine and citalopram, than for paroxetine, sertraline and
escitalopram, and lower with the SNRI devenlafaxine than for
venlafaxine [46]. Information on infant drug exposure is sparse for
some agents and long term data exist only for a few antidepres-
sants, mainly SSRIs. Before initiating antidepressive treatment in
the postpartum period, we recommend consulting the LactMed
database which offers monthly updates on lactation safety [46]. If
the mother was successfully treated with an antidepressant
during pregnancy, or if other antidepressants have been ineffec-
tive, changing medications during breastfeeding is not recom-
mended [46]. Medication discontinuation could lead to relapse.
Due to the many maternal and offspring beneﬁts, breastfeeding
should generally be encouraged also in women with medically
treated postnatal depression [47], but individual risk-beneﬁt
assessments is necessary. The infant should be monitored for
adverse side effects, especially if antidepressants are taken
together with AEDs. Breastfeeding should be performed before
rather than after dose intake. If adverse effects are suspected,
antidepressive - and antiepileptic drug concentrations should be
measured in the infant, and mixed nutrition with formula milk
may be considered. Mothers taking an SSRI during pregnancy and
postpartum may need additional support to succeed with
breastfeeding [46].
4.7. Electroconvulsive therapy (ECT)
There are several case reports on successful treatment with ECT
in patients with epilepsy and psychiatric disease [48], and ECT is
not contraindicated in epilepsy outside pregnancy. However, there
are also reports that describe ECT-induced status epilepticus [49–
51]. A review found evidence for efﬁcacy in treating severe
psychiatric illness during pregnancy in patients without epilepsy
[52]. Possibly ECT-related adverse effects were noted for 5.3% of
the mothers and 3.2% of the children. Transient fetal bradyar-
rhythmias and uterine contractions were among the most frequent
complications, but one fetal death after ECT induced status
epilepticus was also reported [52]. However, long-term effects
on offspring after ECT in pregnancy are not known. In our opinion,
Table 3
Recommendations for management of women with epilepsy in the peripartum period.
Recommendations
Pre-pregnancy planning Optimize AED and antidepressive drug treatment with as few drugs in as low doses as possible. Maintain seizure control.
Notice risk factors Previous psychiatric disease, previous sexual/physical abuse, AED polytherapy, high seizure frequency and adverse
psychosocial factors increase the risk of peripartum depression and anxiety.
Symptom screening Screen for symptoms of anxiety and depression before, during and after pregnancy
Swift treatment Treatment for peripartum psychiatric disease should not be delayed.
Multidisciplinary approach Neurologist, obstetrician, psychiatrist, general practitioner and community midwife/nurse should work together
Non-pharmacological treatment Psychotherapy is recommended for mild to moderate depression and anxiety during pregnancy and breastfeeding
Antidepressive treatment If indicated, SSRIs without a pro-convulsive effect or AED interaction are preferred
Measure serum concentrations Serum levels of AEDs and antidepressive drugs can change due to interaction and metabolic changes in pregnancy
and should be measured
Avoid electroconvulsive therapy ECT should not be used in pregnancy in women with epilepsy
Child care advise Advise expecting parents with epilepsy on safe child care
Monitor child If AEDs and/or antidepressive medications are used during breastfeeding: monitor child for side effects
AED, antiepileptic treatment; SSRI, selective serotonin reuptake-inhibitors; ECT, electroconvulsive therapy.
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as experimental therapy, and is not recommended.
4.8. Recommendations for peripartum depression in WWE
Peripartum psychiatric symptoms are associated with high
seizure frequency and AED use. Therefore the primary aim should
be seizure control with as few AEDs with the lowest possible dose.
This is in line with the recommendations for avoiding teratogenic
effects by in utero exposure to AEDs [38,53] and SSRIs [43]. Testing
of a new antidepressant during pregnancy is not advisable if
a previously used substance has been effective, as the child’s
outcome after exposure to multiple antidepressants in pregnancy
is unknown [43]. Pregnancy planning is therefore important to
optimize AED and antidepressive treatment before conception. It
has been shown that pre-conception planning leads to less use of
AED polytherapy, less switching between drugs and better seizure
control during pregnancy compared to unplanned pregnancies
[54]. In non-pregnant epilepsy patients it is recommended to
screen for psychiatric comorbidities and suicidal ideation before
starting treatment with AEDs as well as during drug titration and
change [20]. Such surveillance should be intensiﬁed throughout
pregnancy and in the postpartum period. A positive effect of
postpartum depression prevention has been shown in high risk
populations [55]. These ﬁndings probably apply also to epilepsy
populations. Patients at risk of psychiatric disease should be
followed up closely. The general practitioner, obstetrical unit,
community midwife/nurse, and other health personnel caring
for the woman should be alerted. In case of depression, anxiety or
other psychiatric symptoms, swift referral to a psychiatrist for
further treatment should be considered. Since some psychoactive
medications reduce the seizure threshold, AEDs may inﬂuence
psychiatric symptoms and both AEDs and antidepressants
potentially affect pregnancy outcome, a multidisciplinary ap-
proach is highly recommended. The possible impact of AED
treatment combined with antidepressive treatment during preg-
nancy and lactation on offspring development is not studied.
Caution is therefore warranted. There is no strong evidence that
favors the superiority of antidepressive drug treatment over
psychotherapy [2,5]. In our opinion, psychotherapy is the ﬁrst line
treatment for mild to moderate depression in pregnant or
breastfeeding WWE. If co-therapy with antidepressants is neces-
sary, a SSRI without AED interaction should be chosen. Drug
clearance can increase during pregnancy for both AEDs and SSRIs
and these drug types may interact [40,43]. Clinical effect and
maternal serum levels of both AEDs and antidepressants should
therefore be monitored and the doses adjusted accordingly
(Table 3) [40].5. Conclusions
WWE often have depression and anxiety during and after
pregnancy. This risk is related to a combination of epilepsy
severity, AED treatment, adverse psychosocial factors, and a
previous history of psychiatric disease or sexual/physical abuse.
Psychiatric disorders are undertreated during pregnancy. Health
personnel should always include an evaluation of psychiatric
disorders in pre-pregnancy planning, during pregnancy, and in
postpartum consultations. Parents with epilepsy should be advised
on safety issues in child care. Single parents may need extra
support. As the consequence of combining AEDs and antidepres-
sive drugs on child outcome is unknown, non-pharmacological
treatment options are recommended as ﬁrst line therapy during
pregnancy and breastfeeding. A multidisciplinary approach is
advisable.
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